Blab Business
QuantHealth Secures $45 Million Series B to Scale AI-Driven Clinical Trial Simulations
Tel Aviv, Israel – On August 4, 2026, QuantHealth, the AI‑driven clinical simulation platform, closed a $45 million Series B round led by growth fund Qumra Capital. Investors also included Sanofi Ventures, Pitango HealthTech, Bertelsmann Healthcare Investments (BHI), Artofin, GC Ventures, NewHealth, Shoni Top, and Esplanade Ventures.
The new capital will expand QuantHealth’s proprietary simulation engine, reinforce scientific validation, and broaden coverage to more than 40 therapeutic indications. The company also plans to enlarge its client‑engagement and go‑to‑market teams to support scaling across clinical and commercial lifecycles.
The platform tackles a longstanding hurdle in drug development: over 90 % of clinical‑stage drugs never reach market, and about 75 % of those failures stem from efficacy or safety concerns. By leveraging large‑scale real‑world data and predictive analytics, QuantHealth’s engine models patient‑level responses to investigational therapies. The company claims the tool reaches up to 90 % predictive accuracy across more than 600 simulated trials.
Biopharmaceutical sponsors can use the platform to test and refine trial protocols, inclusion and exclusion criteria, and commercial outcomes in silico before enrolling patients or allocating capital. The tool is already integrated into the development workflows of 12 of the world’s top 20 pharmaceutical companies, spanning oncology, cardiometabolic, and inflammatory disease sectors.
“Today, clinical development decisions remain largely driven by real‑world iteration—running trials, waiting for results, and making costly adjustments,” said Orr Inbar, CEO and co‑founder. “We’re fundamentally changing that model. With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital.”
The round will also fund the expansion of QuantHealth’s proprietary datasets. The company’s foundation model draws on data from 350 million patients, 700,000 therapeutics, 100,000 molecules, and 180,000 clinical trials. With the new capital, QuantHealth will refine the model and validate its performance across additional disease indications.
Industry observers see the round as evidence of increasing confidence in AI‑driven tools to mitigate drug‑development risk. Sanofi Ventures’ involvement signals a strategic interest in technologies that accelerate pipelines and sharpen go‑no‑go decisions. Pitango HealthTech, a prominent Israeli venture fund, has a history of backing health‑tech companies that scale worldwide.
Moving forward, QuantHealth plans to launch new product offerings that go beyond trial design, adding post‑trial analytics and market‑access modeling. The company also aims to deepen partnerships with pharmaceutical sponsors, providing a more comprehensive suite of services that span the entire clinical‑development journey.
QuantHealth did not disclose a valuation for the Series B round. The $45 million infusion brings total funding to $75 million, cementing the company’s position as a major player in the AI‑driven clinical‑trial arena.
With the pharmaceutical industry still battling high failure rates and mounting development costs, QuantHealth’s simulation platform presents a data‑driven alternative to the traditional trial‑and‑error model. By delivering predictive insights before patient enrollment, the platform could change how sponsors allocate resources and design studies.
The company’s next public disclosure is expected to be a quarterly earnings report, where it may outline how the new capital has affected operational metrics and its client pipeline. Investors and analysts will watch to determine whether the platform’s predictive accuracy yields measurable reductions in trial timelines and costs.
QuantHealth continues to expand into additional therapeutic areas and strengthen ties with existing partners. Regulatory guidance on the use of real‑world evidence in drug approvals could also shape the platform’s adoption.
Over the next few months, stakeholders will watch how QuantHealth uses the Series B funds to accelerate product development, deepen scientific validation, and broaden its market presence across the global pharmaceutical landscape.
The new capital will expand QuantHealth’s proprietary simulation engine, reinforce scientific validation, and broaden coverage to more than 40 therapeutic indications. The company also plans to enlarge its client‑engagement and go‑to‑market teams to support scaling across clinical and commercial lifecycles.
The platform tackles a longstanding hurdle in drug development: over 90 % of clinical‑stage drugs never reach market, and about 75 % of those failures stem from efficacy or safety concerns. By leveraging large‑scale real‑world data and predictive analytics, QuantHealth’s engine models patient‑level responses to investigational therapies. The company claims the tool reaches up to 90 % predictive accuracy across more than 600 simulated trials.
Biopharmaceutical sponsors can use the platform to test and refine trial protocols, inclusion and exclusion criteria, and commercial outcomes in silico before enrolling patients or allocating capital. The tool is already integrated into the development workflows of 12 of the world’s top 20 pharmaceutical companies, spanning oncology, cardiometabolic, and inflammatory disease sectors.
“Today, clinical development decisions remain largely driven by real‑world iteration—running trials, waiting for results, and making costly adjustments,” said Orr Inbar, CEO and co‑founder. “We’re fundamentally changing that model. With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital.”
The round will also fund the expansion of QuantHealth’s proprietary datasets. The company’s foundation model draws on data from 350 million patients, 700,000 therapeutics, 100,000 molecules, and 180,000 clinical trials. With the new capital, QuantHealth will refine the model and validate its performance across additional disease indications.
Industry observers see the round as evidence of increasing confidence in AI‑driven tools to mitigate drug‑development risk. Sanofi Ventures’ involvement signals a strategic interest in technologies that accelerate pipelines and sharpen go‑no‑go decisions. Pitango HealthTech, a prominent Israeli venture fund, has a history of backing health‑tech companies that scale worldwide.
Moving forward, QuantHealth plans to launch new product offerings that go beyond trial design, adding post‑trial analytics and market‑access modeling. The company also aims to deepen partnerships with pharmaceutical sponsors, providing a more comprehensive suite of services that span the entire clinical‑development journey.
QuantHealth did not disclose a valuation for the Series B round. The $45 million infusion brings total funding to $75 million, cementing the company’s position as a major player in the AI‑driven clinical‑trial arena.
With the pharmaceutical industry still battling high failure rates and mounting development costs, QuantHealth’s simulation platform presents a data‑driven alternative to the traditional trial‑and‑error model. By delivering predictive insights before patient enrollment, the platform could change how sponsors allocate resources and design studies.
The company’s next public disclosure is expected to be a quarterly earnings report, where it may outline how the new capital has affected operational metrics and its client pipeline. Investors and analysts will watch to determine whether the platform’s predictive accuracy yields measurable reductions in trial timelines and costs.
QuantHealth continues to expand into additional therapeutic areas and strengthen ties with existing partners. Regulatory guidance on the use of real‑world evidence in drug approvals could also shape the platform’s adoption.
Over the next few months, stakeholders will watch how QuantHealth uses the Series B funds to accelerate product development, deepen scientific validation, and broaden its market presence across the global pharmaceutical landscape.
